• Repositive Launches Patient Derived Xenographs Database

    Bio-IT World | Software company Repositive aims to make PDX mice, crucial animal models for studying human-like cancers, searchable across vendors by indexing hundreds of different repositories in one platform.

    Aug 8, 2016

  • Cray stock drops 30% as CEO says supercomputer market is slowing

    The Seattle Times | Cray CEO Peter Ungaro considers the slowdown in the supercomputer market as "temporary."

    Aug 4, 2016

  • Recommended Summer Reading For Biotech And Pharmaceutical Pros

    Forbes | Biotech and pharmaceutical industry professionals are busy people like everyone else. But they still find time to read books, especially when schedules slow down a tad during summer. So what are biotech professionals reading, and recommending, these days?

    Aug 3, 2016

  • Editas, MGH Announce Exclusive Licensing Agreement

    Bio-IT World Briefs | Editas Medicine and Massachusetts General Hospital (MGH) announced an exclusive licensing agreement this morning, under which Editas can access intellectual property and technology related to high-fidelity Cas9 nucleases and Cas9 PAM variants that will enable the company to address an expanded range of genetically-defined diseases with the potential for enhanced specificity.

    Aug 3, 2016

  • Legal Confusion Threatens to Slow Data Science

    Nature News & Comment | Daniel Himmelstein built a free online network to meld data from 28 public sources on links between drugs, genes, and diseases. Then he spent months chasing legal permission to republish the online data sets.

    Aug 3, 2016

  • Biogen Draws Takeover Interest from Rival Drugmakers

    WSJ | Biotechnology giant Biogen Inc. has drawn takeover interest from drug companies including Merck & Co. and Allergan PLC, raising the possibility of another huge deal in the health-care industry.

    Aug 2, 2016

  • Setting the Body’s ‘Serial Killers’ Loose on Cancer

    The New York Times | After a long, intense pursuit, researchers are close to bringing to market a daring new treatment: cell therapy that turbocharges the immune system to fight cancer.

    Aug 2, 2016

  • Q&A Glaxo Exec Says Bioelectronics Is Not Science Fiction

    STAT | Glaxo and Verily Life Sciences will invest $715 million in Galvani Bioelectronics and hope to win approval for their implantable devices in several years.

    Aug 1, 2016

  • Data Management, New NGS Panels: News and Briefs

    Bio-IT World Briefs | News and product launches from bio IT, clinical IT, and diagnostics technologies include data management installation at Scripps Research Institute and new NGS panels for detection of extremely rare (low-frequency) mutations.

    Aug 1, 2016

  • IBMs cloud CTO Were in this game to win

    Computerworld | An industry focus is one of the key factors IBM is betting will set it apart from cloud competitors including Google, Microsoft and Amazon Web Services, IBM's top cloud exec says.

    Jul 29, 2016

  • How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company

    Forbes | BioMarin became one of the world's most valuable biotechs by jettisoning costly distractions and focusing on one thing: treating some of the rarest diseases on the planet.

    Jul 28, 2016

  • Taking Genomic Data Global

    MIT Technology Review | Startups focused on Asia are among those aiming to bring precision medicine to far more people.

    Jul 28, 2016

  • Microsoft’s Iowa data center cluster to reach 3.2M square feet

    Computerworld | Microsoft is creating some 3.2 million square feet of data center space in the West Des Moines, Iowa, area but in three separate locations. The combined investment is about $3.5 billion.

    Jul 28, 2016

  • Eli Lilly CEO Lechleiter to Retire After Eight-Year Stint

    Xconomy | After eight years at the helm of Eli Lilly, a tenure characterized by a steadfast belief in home-grown research, rather than deals, John Lechleiter is retiring. David Ricks, who currently runs Lilly's diversified bio-medicines unit-which develops drugs for neurological and cardiovascular disorders, among other diseases-will be named CEO on Jan. 1

    Jul 27, 2016

  • Time to Remodel the Journal Impact Factor

    Nature News & Comment | Nature and the Nature journals are diversifying their presentation of performance indicators. Impact factor is crude and also misleading. It effectively undervalues papers in disciplines that are slow-burning or have lower characteristic citation rates. Accordingly, Nature has updated its online journal metrics page to include an array of additional bibliometric data.

    Jul 27, 2016

  • Nvidias Quadro P6000 GPU blasts out 12 teraflops of performance

    Computerworld | Nvidia keeps upping the performance with each new GPU based on the Pascal architecture. Its latest, the Quadro P6000, can deliver 12 teraflops of single-precision performance, a teraflop more than the Titan X unveiled just last week.

    Jul 26, 2016

  • Inside Genomics Pioneer Craig Venter’s Latest Production

    MIT Technology Review | His startup is using data to unlock the connections between DNA and illness.

    Jul 25, 2016

  • Chinese scientists to pioneer first human CRISPR trial

    Nature News & Comment | Gene-editing technique to treat lung cancer is due to be tested in people in August. Sichuan University's West China Hospital in Chengdu plans to inject lung cancer patients with cells modified using the CRISPR-Cas9 gene-editing technique. The clinical trial received ethical approval from the hospital July 6.

    Jul 22, 2016

  • Bioz Launches Life Sciences Search Engine

    Bio-IT World | Bioz, Inc. came out of stealth today with the introduction of a search engine for life science experimentation. The company, started by Stanford research scientist Karin Lachmi and serial entrepreneur Daniel Levitt, also announced $3 million in seed funding, led by 5AM Ventures.

    Jul 20, 2016

  • The Seven Bridges CGC: Boon for Bioinformatics, Success for a Startup

    Bio-IT World It's been a busy two years for Seven Bridges. In May 2014, Seven Bridges was introducing its open source cancer informatics pipeline: open source algorithms running on the proprietary Seven Bridges cloud infrastructure. Less than six months later, the company was awarded one of three National Cancer Institute Cloud Pilot contracts.

    Jul 19, 2016